Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population

OBJECTIVES: The cost of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection may contribute to treatment disparities. However, few data exist on factors associated with DAA initiation. METHODS: We conducted a retrospective cohort study of HCV-infected Kaiser Permanente Norther...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Public Health Rep
Autores principales: Marcus, Julia L., Hurley, Leo B., Chamberland, Scott, Champsi, Jamila H., Gittleman, Laura C., Korn, Daniel G., Lai, Jennifer B., Lam, Jennifer O., Pauly, Mary Pat, Quesenberry, Charles P., Ready, Joanna, Saxena, Varun, Seo, Suk I., Witt, David J., Silverberg, Michael J.
Formato: Artigo
Lenguaje:Inglês
Publicado: SAGE Publications 2018
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6055302/
https://ncbi.nlm.nih.gov/pubmed/29750893
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0033354918772059
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares